

## SELECTED PUBLICATIONS

David E. Wazer, MD

## TEXTBOOKS AND MONOGRAPHS

- 1) **D.E. Wazer**, guest editor of “Surgical Oncology Clinics of North America”, “Practical Radiation Oncology for the Surgical Oncologist”, W.B. Saunders Co., Philadelphia, PA; July, 2000.
- 2) **D. E. Wazer**, co-editor (with R. Schmidt-Ullrich, T. Bortfeld, W. De Neve), “Image-guided IMRT”. Springer-Verlag, Heidelberg. Released December, 2005
- 3) **D. E. Wazer**, (lead and managing editor). Co-editors: D. Arthur, F. Vicini. “Accelerated Partial Breast Irradiation”. Springer-Verlag. In production.
- 4) **D. E. Wazer** (associate editor) “Principles and Practice of Radiation Oncology, 5<sup>th</sup> Edition” (with E. Halperin, C. Perez, L. Brady). Lippincott, Williams and Wilkins, In production.

## REFEREED PAPERS

- 1) M. Stanley, J. Rotrosen, **D. Wazer**, A. Lautin and S. Gershon; Tardive Dyskinesia and Metoclopramide. *Lancet*, 1979; ii:1190.
- 2) J. Rotrosen, M. Stanley, C. Kuhn, **D. Wazer** and S. Gershon; Experimental Dystonia Induced by Quaternary Chlorpromazine. *Neurology*, 30; 878-881, 1980.
- 3) A.Lautin, **D. Wazer**, M. Stanley, J. Rotrosen and S. Gershon; Chronic Treatment with Metoclopramide Induces Behavioral Supersensitivity to Apomorphine and Enhances Binding of 3H-Spiroperidol to Rat Striata. *Life Sciences*, 27; 306-316, 1980.
- 4) J. Rotrosen, M. Stanley, A. Lautin, **D. Wazer** and S. Gershon; Discrimination of Functionally Heterogeneous Receptor Subpopulations: Antipsychotic and Antidopaminergic Properties of Metoclopramide. *Psychopharm. Bull.* 17; 110-113; 1981.
- 5) M. Stanley, **D. Wazer**, J. Virgilio, C. Kuhn, D. Benson and L. Meyerson; Lack of Potency of Metoclopramide's Metabolites in Various Dopaminergic Models. *Pharmac., Biochem., and Behav.*, 18; 262-266, 1983.
- 6) M. Stanley and **D. Wazer**; High Plasma Concentrations of Metoclopramide are not Detected by Radioreceptor Assay. *Neuropsychobiology* 10(2-3); 108-110, 1983.
- 7) **D. Wazer**, D. Cordasco, D. Segarnick, A. Lippa, L. Meyerson, D. Benson and J. Rotrosen; Norepinephrine Stimulation of Phospholipid Methylation in Rat Cortical Synaptosomes: Fact or Artifact? *Life Sciences* 31; 1184-1199, 1984.

- 8) D. Cordasco, **D. Wazer**, D. Segarnick, A. Lautin, A. Lipa and J. Rotrosen; Phospholipid Methylation in Platelets and Brain. *Psychopharm. Bull.*, 18(3), 193-197, 1982.
- 9) **D. Wazer** and J. Rotrosen; Murine Lymphocytes Lack Clearly Defined Receptors for Muscarinic and Dopaminergic Ligands. *J. of Pharm. and Pharmac.*, 36(12); 83-84, 1984.
- 10) **D. Wazer**, M. Keisch, W. Koch, C. Karmody and R. Schmidt-Ullrich; Combined Radiotherapy and Composite Resection in the Management of Advanced Head and Neck Cancer. *Strahlentherapie und Onkologie*, 165(1); 18-23, 1989.
- 11) **D. Wazer**, O. Tercilla, P-S. Lin and R. Schmidt-Ullrich; Modulation in the Radiosensitivity of MCF-7 Human Breast Carcinoma Cells by 17 $\beta$ -Estradiol and Tamoxifen. *Brit. Jour of Radiol.*, 62;1079-1083, 1989.
- 12) **D. Wazer**, R. Schmidt-Ullrich, W. Chasin, A. Wu and M. Buscher; High Dose Boost Irradiation Techniques for Carcinoma of the Nasopharynx. *Am. J. Otolaryngol.* 10;173-180, 1989.
- 13) R. Schmidt-Ullrich, **D.E. Wazer**, O. Tercilla, H. Safaii, D. Marchant, T. Smith, M. Homer, and N. Robert; Tumor Margin Assessment as a Guide to Optimal Conservation Surgery and Irradiation in Early Stage Breast Carcinoma. *Int. Jour. Rad. Biol. Onc. Phys.*, 17;733-738, 1989.
- 14) **D. E. Wazer**, M. Sinesi, R. Schmidt-Ullrich, T. Smith, H. Safaii, D. Marchant, N. Robert, and M. Homer; The Importance of surgical and pathological determinants of Tumor Margin status in Breast Conservation Therapy. *Breast Disease*, 4;285-292, 1991.
- 15) **D. E. Wazer**, R. Schmidt-Ullrich, M. Homer, H. Safaii, O. Tercilla, T. Smith, D. Marchant, and N. Robert; The Utility of Pre-operative Physical Examination and Mammography for Detecting an Extensive Intraductal Component in Early Stage Breast Carcinoma. *Breast Disease*, 3;181-185, 1990.
- 16) H. Madoc-Jones, **D. E. Wazer**, R. G. Zamenhof, O. Harling, J. Bernard; Clinical Considerations for Neutron Capture Therapy of Brain Tumors. *Basic Life Sci* 54:23-35; 1990.
- 17) R. G. Zamenhof, S. D. Clement, O. Harling, J. Brenner, **D. E. Wazer**, H. Madoc-Jones, J. Yanch; Monte Carlo Based Dosimetry and Treatment Planning for Neutron Capture Therapy of Brain Tumors. *Basic Life Sci* 54:283-305; 1990.
- 18) C. Hillyer, R. Comenzo, K. Miller, **D. Wazer**, J. Desforges, R. Rudders, D. Scheinkein, R. Abrams, E. Berkman; Prompt Engraftment Using Autologous Peripheral Blood Stem Cells (PBSC) in Double Autologous Bone Marrow Rescue (BMR). *Amer. Jour. Hematology* 36:152-153, 1991.

- 19) R. Schmidt-Ullrich, C. Johnson, **D. Wazer**, G. Masko. Accelerated Superfractionation for Advanced Carcinoma of the Head and Neck: Concomitant Boost Technique. *Int. J. Rad. Oncol. Biol. Phys.* 23(3):563-568, 1991.
- 20) **D. Wazer**, M. Joyce, G. Solares, R. Schmidt-Ullrich. Proliferative inhibition of human breast carcinoma cells by high concentrations of 17 $\beta$ -estradiol does not alter radiosensitivity. *Breast Cancer Research and Treatment* 18:141-148, 1991.
- 21) O. Harling, R. Zamenhof, J. Yanch, R. Choi, G. Solares, R. Rogus, D. Moulin, L. Johnson, I. Olmez, S. Wirdzek, J. Bernard, C. Nwanguma, **D. Wazer**, S. Saris, C. Sledge, H. Madoc-Jones; Boron Neutron Capture and Radiation Synovectomy Research at the MIT Research Reactor. *J. Nucl. Sci. Engin.* 110:330-348, 1992.
- 22) R. Schmidt-Ullrich, W. Chan, K. Valerie, **D. E. Wazer**, P.S. Lin; Expression of estrogen receptor and transforming growth factor alpha in MCF-7 cells after exposure to fractionated irradiation. *Int. J. Radiat. Biol.*, 61(3):405-315, 1992.
- 23) R. Zamenhof, H. Madoc-Jones, O. Harling, **D. Wazer**, S. Saris, J. Yanch. The neutron capture therapy research program at New England Medical Center and the Massachusetts Institute of Technology. Proceedings of the International Society of Neutron Capture Therapy, Plenum press, 1992.
- 24) R. Zamenhof, J. Brenner, J. Yanch, **D. Wazer**, H. Madoc-Jones, S. Saris, O. Harling. Treatment planning for neutron capture therapy of glioblastoma multiforme using an epithermal neutron beam from the MITR-II research reactor and monte carlo simulation. Proceedings of the International Society of Neutron Capture Therapy, Plenum press, 1992.
- 25) G. Solares, R. Zamenhof, S. Saris, **D. Wazer**, S. Kerley, M. Joyce, H. Madoc-Jones, L. Adelman, O. Harling. Biodistribution and pharmacokinetics of p-boronophenylalanine in C7BL/6 mice with GL261 intracerebral tumors and survival following neutron capture therapy. Proceedings of the International Society of Neutron Capture Therapy, Plenum press, 1992.
- 26) D. D. Karp, B. D. T. Daly, N. Robert, R. Abrams, T. O'Connor, N. DiMartino, J. Diehl, **D. E. Wazer**, B. Willett, R. Heidbreder, M. Bankoff, B. Fanburg, L. Faling; A randomized pilot study of radiation therapy with or without concomitant cisplatin and etoposide as adjuvant therapy in non small cell lung cancer. p. 325-336 in "Lung cancer differentiation: implications for diagnosis and treatment". eds. S. Bernal and P. Hesketh, Marcel Dekker, New York, 1992.
- 27) C. Johnson, R. Schmidt-Ullrich, and **D. E. Wazer**; Concomitant boost technique using accelerated superfractionated radiotherapy for advanced squamous cell carcinoma of the head and neck. *Cancer*, 69:2749-2754, 1992.
- 28) **D. E. Wazer**, T. DiPetrillo, R. Schmidt-Ullrich, L. Weld, T. Smith, D. Marchant, N. Robert. Factors influencing cosmetic outcome and complication risk after conservative surgery and radiotherapy for early stage breast carcinoma. *Jour. Clin. Oncol.*, 10(3):356-363, 1992.

- 29) **D. E. Wazer**, M. Joyce, W. Chan, R. Schmidt-Ullrich. The effects of tamoxifen on the radiosensitivity of hormonally responsive and un-responsive breast carcinoma cells. *Rad Oncol Invest*, 1(1):20-28, 1993.
- 30) R. Schmidt-Ullrich, **D. E. Wazer**, T. DiPetrillo, T. Smith, D. Marchant. Breast Conservation therapy for early stage breast carcinoma with outstanding 10-year locoregional control rates. A case for aggressive therapy to the tumor bearing quadrant. *Int J Radiat Oncol Biol Phys*, 27:545-552, 1993.
- 31) S. Saris, G. Solares, **D. Wazer**, G. Cano, S. Kerley, M. Joyce, L. Adelman, O. Harling, H. Madoc-Jones, R. Zamenhof. Boron neutron capture therapy for primary murine brain tumors. *Cancer Res*. 52:4672-4677, 1992.
- 32) **D. E. Wazer**, M. Joyce, L. Jung, V. Band. Alterations in growth phenotype and radiosensitivity after fractionated irradiation of breast carcinoma cells from a single patient. *Int J Radiat Oncol Biol Phys*, 26:81-88, 1993.
- 33) K. Radie-Keane, **D. E. Wazer**, R. Schmidt-Ullrich. Loco-regional control of inflammatory carcinoma of the breast with accelerated superfractionated radiotherapy. *Breast Dis* 7:59-68, 1994.
- 34) R. Graham, M. Atkins, D. Karp, **D. Wazer**, A. Hackford. Local excision of rectal carcinoma: Early results with combined chemoradiation therapy using 5-flourouracil and leucovorin. *Dis Colon Rectum*, 37:308-312, 1994.
- 35) C. Hillyer, J. Hall, D. A. Lackey, **D. E. Wazer**. Development of a colorimetric dosimeter for quality control of blood units and irradiators. *Transfusion*, 33:898-901, 1993.
- 36) E. Oates, P. Touliopoulos, **D. E. Wazer**. Demonstration of unilateral sialadenitis on post-radiotherapy Gallium-67 Citrate imaging. *J. Nucl. Med.*, 34(6):953-954, 1993.
- 37) R. Zamenhof, **D. E. Wazer**, J. Bernard, O. Harling, T. Dipetrillo, H. Madoc-Jones, J. Coderre, A. Meek. Federal and institutional approvals necessary prior to a US clinical trial of neutron capture therapy. Proceedings of the fifth International Symposium on Neutron Capture Therapy, 1993.
- 38) O. Harling, R. Rogus, J. Chabeuf, S. Yam, F. Lambert, J. Yanch, R. Zamenhof, G. Solares, **D. E. Wazer**, H. Madoc-Jones. Preparations for clinical trials of NCT at the MIT reactor and the New England Medical Center. Proceedings of the Fifth International Symposium on Neutron Capture Therapy, 1993.
- 39) S. Hauser, L. Calorini, **D. E. Wazer**, S. Gattoni-Celli. Radiation-enhanced expression of major histocompatibility complex (MHC) class I antigen H-2Db in B-16 melanoma cells. *Cancer Research*, 53:1952-1955, 1993.

- 40) G. Solares, R. Zamenhof, **D. E. Wazer**, T. DiPetrillo, S. Saris, G. Cano, O. Harling. Effects of fractionation of boron neutron capture therapy in a mouse glioma model. Proceedings of the Fifth International Symposium on Neutron Capture Therapy, 1993.
- 41) R. Zamenhof, J. Brenner, J. Yanch, C. Gung, E. Redmond, **D. Wazer**, H. Madoc-Jones. Monte Carlo based treatment planning for neutron capture therapy using custom designed phantoms automatically generated from CT data. Proceedings of the Fifth International Symposium on Neutron Capture Therapy. 1993.
- 42) O. Tercilla, **D. E. Wazer**, R. Schmidt-Ullrich. Accelerated superfractionation for re-irradiation of head and neck neoplasms. *Strahlentherapie und Onkologie* 169:285-290, 1993.
- 43) M. Engler, B. Curran, J. Tsai, E. Sternick, W. Selles, **D. E. Wazer**, W. Mason, T. Sailor, T. Mackie. Fine tuning of linear accelerator accessories for stereotactic radiotherapy. *Int J Radiat Oncol Biol Phys*, 28:1001-1008, 1994.
- 44) C. Johnson, S. Khandelwal, R. Schmidt-Ullrich, J. Ravalese, **D. E. Wazer**: The influence of quantitative tumor volume measurements on local control in advanced head and neck cancer using concomitant boost accelerated superfractionated irradiation. *Int J Radiat Oncol Biol Phys*, 32:635-641, 1995.
- 45) R. Schmidt-Ullrich, C. Johnson, S. Khandewal, **D. E. Wazer**: Concomitant boost accelerated superfractionated irradiation for the treatment of advanced carcinomas of the oral cavity and oropharynx. Recent Results in Cancer Res., Ganzer, Pape, Schmitt eds. 134:69-79, Berlin. Springer Verlag, 1994.
- 46) **D. E. Wazer**, Q. Chu, X. Liu, Q. Gao, H. Safaii, V. Band: Loss of p53 protein during radiation-transformation of primary human mammary epithelial cells. *Molec Cell Biol*, 14:2468-2478, 1994.
- 47) X. Liu, H. Band, Q. Gao, **D. E. Wazer**, Q. Chu, V. Band: Tumor cell-specific loss of p53 protein in a model of multi-step breast tumorigenesis. *Carcinogenesis*, 15:1969-1973, 1994.
- 48) **D.E. Wazer**, I. Gage, S. Krosnick, M. Homer, C. Schmid: Age-related differences in patients with non-palpable breast carcinomas. *Cancer* 78:1432-1437, 1996.
- 49) **D. E. Wazer**, J. Erban, N. Robert, T. Smith, D. Marchant, T. DiPetrillo, R. Schmidt-Ullrich: Breast conservation for clinically node negative cancer without axillary dissection in elderly women. *Cancer*, **74**:878-883, 1994.
- 50) **D. E. Wazer**, X. Liu, Q. Chu, Q. Gao, V. Band. Immortalization of distinct human mammary epithelial cell types by human papilloma virus-16 E6 or E7. *Proc Natl Acad Sci USA* 92:3687-3691, 1995.
- 51) O. K. Harling, R. Zamenhof, G. Solares, J Yanch, **D. E. Wazer**, R. Rogus, J. Chabeuf, S. Yam, J. Bernard, G. Cano, T, DiPetrillo, H. Madoc-Jones. Preparations for phase I clinical

trials of Boron Neutron Capture Therapy at the MIT reactor and New England Medical Center. *Rad Oncol Invest* 2:109-118, 1994.

- 52) R. Schmidt-Ullrich, **D. E. Wazer**, O. Tercilla, H. Safaii, D. Marchant, T. Smith, N. Robert, M. Homer. Tumor margin assessment as a guide to optimal conservation surgery and irradiation in early stage breast carcinoma: A Year Book Quarterly (C.M. Balch ed.) Mosby Year Book, Chicago, Ill., 1990.
- 53) R. Schmidt-Ullrich, **D. E. Wazer**, D. Marchant, T. Smith, H. Safaii, N. Robert. Breast conserving therapy with out-standing 10-year locoregional control rates. A case for aggressive treatment to the tumor-bearing quadrant. in Year Book of Obstetrics and Gynecology; Mosby-Year Book. 1995.
- 54) **D. E. Wazer**, R. Schmidt-Ullrich, C. Schmid, H. Safaii. The value of breast lumpectomy margin assessment as a predictor of residual tumor burden. *Int J Radiat Oncol Biol Phys* 38:291-299, 1997.
- 55) **D. E. Wazer**, P. Mckeough, H. Madoc-Jones. Splenic Irradiation for patients with Polycythemia Vera. *Rad Oncol Invest*. 3:167-171, 1995.
- 56) H. Madoc-Jones, R. Zamenhof, G. Solares, O. Harling, C. Yam, K. Riley, **D. Wazer**, G. Rogers, M. Atkins. A Phase I dose-escalation trial of Boron Neutron Capture Therapy for subjects with metastatic subcutaneous melanoma of the extremities. Proceedings of the Fifth International Meeting on Progress in Radio-Oncology, Salzberg, Vienna, May 10-14, 1995, Plenum Publishing.
- 57) Q. Gao, S. Hauser, X.L. Liu, **D. E. Wazer**, H. Madoc-Jones, V. Band. Mutant p53-induced immortalization of primary human mammary epithelial cells. *Cancer Res*. 56:3129-3133, 1996.
- 58) X. Liu, **D. E. Wazer**, V. Band. Identification of a novel protease-like gene whose expression is down-regulated during breast cancer progression. *Cancer Res*. 56:3371-3379, 1996.
- 59) **D. E. Wazer**, V. Band. Molecular mechanisms of immortalization of human mammary epithelial cells. *Rad Oncol Invest*. 3:430-434, 1996.
- 60) M. Carol, R. Grossman, R. Selker, J. Wu, B. Butler, S. Woo, M. Wizenburg, **D. E. Wazer**, M. Ling, W. Grant, M. Engler, J. Tsai. Preliminary Clinical Experience with the Peacock Intensity Modulation 3-D Conformal Radiation Therapy System. in "*Radiosurgery 1995*", Proceedings of the 2nd ISRS meeting, Boston, Massachusetts. Basel, Karger, 1996, vol 1, pp 327-335.
- 61) W. Cano, G. Solares, T. DiPetrillo, S. Meylerts, S. Lin, R. Zamenhof, S. Saris, J. Duker, E. Goad, H. Madoc-Jones, **D.E. Wazer**. Toxicity associated with boronophenylalanine and cranial neutron irradiation. *Rad Oncol Invest*. 3:108-118, 1995.

- 62) **D.E. Wazer**, B. Kramer, C. Schmid, R. Ruthazer, K. Ulin, R. Schmidt-Ullrich. Factors determining outcome in patients treated with interstitial implantation as a radiation boost for breast conservation therapy. *Int J Radiat Oncol Biol Phys* 39:381-393, 1997.
- 63) S.N. Boyer, **D.E. Wazer**, V. Band. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteosome pathway. *Cancer Res* 56:4620-4624, 1996.
- 64) L.J. Pierce, B. McCormick, B. Haffty, L.J. Solin, F. Vicini, **D.E. Wazer**, A. Recht, M. Strawderman, A.S. Lichter. The use of radiotherapy in the conservative management of Paget's Disease of the breast. *Cancer* 80:1065-1072, 1997.
- 65) K. Ulin, L. Bornstein, M. Ling, J. Wu, B. Curran, **D. E. Wazer**. A technique for accurate planning of stereotactic brain implants prior to head ring fixation. *Int J Radiat Oncol Biol Phys* 39:757-767, 1997.
- 66) J. Tsai, **D. E. Wazer**, M. Ling, J. Wu, M. Fagundes, T. DiPetrillo, B. Kramer, M. Koistinen, M. Engler. Dosimetric verification of the dynamic intensity-modulated radiation therapy of 92 patients. *Int J Radiat Oncol Biol Phys* 40:1213-1230, 1998.
- 67) S. A. Vora, **D.E. Wazer**, M. Homer. Management of microcalcifications that develop at the lumpectomy site following breast conserving irradiation. *Radiology* 203:667-671, 1997.
- 68) M. Geiger, J.K. Wu, M.N. Ling, **D.E. Wazer**, J. Tsai, M. Engler. Response of intracranial melanoma metastases to stereotactic radiosurgery. *Rad Oncol Invest* 5:72-80, 1997.
- 69) B. Kramer, **D.E. Wazer**, M. Engler, J. Tsai, M.N. Ling. Comparison of stereotactic radiosurgery to optimized intensity modulated radiotherapy for an irregularly shaped intracranial target. *Rad Oncol Invest*, 6:18-25, 1998.
- 70) **D.E. Wazer**, J. Morr, J. Erban, C. Schmid, R. Ruthazer, R. Schmidt-Ullrich. The effect of post-radiation tamoxifen on local control and cosmetic outcome in the conservatively treated breast. *Cancer*, 80:732-740, 1997.
- 71) J. Tsai, M. Engler, M. Ling, J. Wu, T. DiPetrillo, **D. E. Wazer**. A non-invasive immobilization system for dynamic intensity modulated radiation therapy. *Int J Radiat Oncol Biol Phys* 43:455-467; 1999.
- 72) **D. E. Wazer**. Age-related differences in patients with nonpalpable breast carcinomas. *Breast Diseases:A Yearbook Quarterly*. C. M. Balch, ed., 1997.
- 73) **D. E. Wazer**, R. Schmidt-Ullrich, R. Ruthazer, C. Schmid, R. Graham, H. Safaii, J. Rothschild, J. McGrath, J. Erban. Factors influencing outcome with breast conserving irradiation with margin-directed dose escalation to the tumor bed. *Int J Radiat Oncol Biol Phys* 40:851-858, 1998.

- 74) R. A. Graham, A. W. Hackford, **D. E. Wazer**. Local Excision with chemoradiation therapy for rectal carcinoma: A safe alternative for more advanced tumors? *J Surg Oncol* 70:235-238; 1999.
- 75) S. Vora, **D. E. Wazer**, M. Homer. Management of microcalcifications that develop at the lumpectomy site after breast-conserving therapy. *Breast Diseases: A Yearbook Quarterly*, p. 369; Mosby Year book. St. Louis, Mo, January, 1998.
- 76) **D. E. Wazer**, R. Schmidt-Ullrich, C. H. Schmid, H. Safaii. The value of breast lumpectomy margin assessment as a predictor of residual tumor burden. *Breast Diseases: A Yearbook Quarterly*, Mosby Yearbook, St. Louis, MO, March, 1998.
- 77) Y. Cao, Q. Gao, **D. E. Wazer**, V. Band. Abrogation of wild-type p53-mediated transactivation is insufficient for p53-induced immortalization of normal human mammary epithelial cells. *Cancer Res* 57:5584-5589, 1997.
- 78) G. Jabro, D. Schenkein, K. Miller, T. Boyle, G. Berkman, **D. E. Wazer**. The role of splenic irradiation in patients with chronic myelogenous leukemia undergoing allogeneic bone marrow transplantation. *Biology of Blood and Marrow Transplantation* 5:173-179; 1999.
- 79) Q. Gao, S. Srinivasan, S. Boyer, **D. E. Wazer**, V. Band. The high-risk HPV E6 oncoproteins bind to a novel putative GTPase activating protein, E6TP1, and target it for degradation. *Molec Cell Biol* 19:733-744; 1999.
- 80) **D. E. Wazer**, V. Band. Molecular and Anatomic Considerations in the pathogenesis of breast cancer. *Rad Oncol Invest* 7:1-12; 1999.
- 81) D. Arthur, R. Friedman, **D. E. Wazer**, L. Kachnic, C. Amir, H. Bear, W. Lawrence, M. Hackney, T. Smith, R. K. Schmidt-Ullrich. Accelerated superfractionated radiotherapy for inflammatory breast carcinoma: complete response predicts outcome and allows for breast conservation. *Int J Radiat Oncol Biol Phys* 44:289-296, 1999.
- 82) B. A. Kramer, D.W. Arthur, K. Ulin, R. Schmidt-Ullrich, R. Zwicker, **D. E. Wazer**. Cosmetic outcome in patients receiving an interstitial implant as part of breast conservation therapy. *Radiology* 213:61-66; 1999.
- 83) J. Goyal, K. Smith, J. Cowan, **D. E. Wazer**, S. Lee, V. Band. The role for NES1 serine protease as a novel tumor suppressor. *Cancer Res.* 58:4782-4786, 1998.
- 84) **D. E. Wazer**, R. K. Schmidt-Ullrich, R. Ruthazer, T. DiPetrillo, T. Boyle, J. Kanski, H. Safaii. The influence of age and EIC histology upon breast lumpectomy margin assessment as a predictor of residual tumor. *Int J Rad Oncol Biol Phys.* 45:885-891, 1999.
- 85) **D. E. Wazer**, G. Jabro, R. Ruthazer, C. Schmid, H. Safaii, R.K. Schmidt-Ullrich. Extent of Margin positivity as a predictor for local recurrence after breast conserving irradiation. *Rad Oncol Invest* 7:111-117; 1999.

- 86) G.S. Rogers and **D.E. Wazer**. New approaches to treating advanced melanoma: adjuvant treatment of high-risk primary melanoma and boron neutron capture therapy. *Semin Cutan Med Surg* 16:165-173; 1997.
- 87) G. Jabro, **D.E. Wazer**, R. Ruthazer. The importance of loco-regional radiotherapy with conventional or high-dose chemotherapy in the management of breast cancer patients with  $\geq 10$  positive axillary nodes. *Breast Diseases: A Yearbook Quarterly*, Mosby- Year Book, December, 1999.
- 88) G. Jabro, **D.E. Wazer**, R. Ruthazer, R. Lum, N. Sklar, D. Goldman, D. Enegess, J. Erban. The importance of loco-regional radiotherapy with conventional or high-dose chemotherapy in the management of breast cancer patients with  $\geq 10$  positive axillary nodes. *Int. J. Radiat. Oncol. Biol. Phys.* 44:273-280, 1999.
- 89) S. Ratsch, Q. Gao, S. Srinivasan, **D.E. Wazer**, V. Band. Multiple genetic changes are required for efficient immortalization of different subtypes of normal human mammary epithelial cells. *Radiat Res* 155:143-150, 2001.
- 90) Q. Gao, A. Kumar, S. Srinivasan, L. Singh, Y. Ono, **D.E. Wazer**, V. Band. PKN binds and phosphorylates human papillomavirus E6 oncoprotein. *J Biol Chem* 275:14824-14830; 2000.
- 91) C. R. King, T. A. DiPetrillo, **D. E. Wazer**. Optimal radiotherapy for prostate cancer: Predictions for conventional external beam, IMRT, and brachytherapy from radiobiologic models. *Int J Radiat Oncol Biol Phys* 46:165-172; 2000.
- 92) Q. Gao, L. Singh, S. Srinivasan, **D. E. Wazer**, V. Band. HPV16 E6 induced degradation of E6TP1 correlates with its ability to immortalize human mammary epithelial cells. *J Virol* 75:4459-4466, 2001.
- 93) **D. E. Wazer**, D. Lowther, T. Boyle, K. Ulin, A. Neuschatz, R. Ruthazer, T. A. DiPetrillo. Clinically evident fat necrosis in women treated with HDR brachytherapy alone for early stage breast cancer. *Int J Radiat Oncol Biol Phys* 50:107-111, 2001.
- 94) J.E. Mignano, M. Engler, J-S. Tsai, **D.E. Wazer**. Comparison of radiobiologic modeling for one- and two-isocenter dose distributions applied to ellipsoid radiosurgery targets. *Int J Radiat Oncol Biol Phys*, 49:833-837; 2001.
- 95) A. Mahajan, M.J. Rivard, E.R. Nunez, **D.E. Wazer**. A high dose rate Cf-252 brachytherapy protocol for cervical carcinoma. In: "*Trans. Of the American Nuc. Soc. And the European Nuc. Soc., Intl. Conf. On Nuc. Sci. and Technology: Supporting Sustainable Development Worldwide*, edited by Christine A. Yoelin, Washington DC (ANS Inc., La Grange Park, IL, 2000) **83**, pp. 314-315.
- 96) B. Li, J. Goyal, S. Dhar, G. Dimri, E. Evron, S. Sukumar, **D. E. Wazer**, V. Band. CpG methylation as a basis for breast tumor-specific loss of NES1/kallakrein 10 expression.

*Cancer Res* 61:8014-8021;2001

- 97) C. Mayo, P. Chougule, B. Sharaf, C. King, N. Miele, **D. Wazer**, D. Williams. A comparative dosimetry study of Sr-90 and Ir-192 used in intravascular brachytherapy. *Cardiovasc Radiat Med* 2:54-55; 2001
- 98) Q. Gao, L. Singh, A. Kumar, J.M. Huibregtse, S. Beaudenon, S. Srinivasan, **D. E. Wazer**, H. Band, V. Band. HPV E6 induced degradation of E6TP1 is mediated by E6AP ubiquitin ligase. *Cancer Res* 62:3315-3321; 2002.
- 99) **D. E. Wazer**, L. Berle, T. DiPetrillo, B. Cady, R. Graham, T. Graves, K. Ulin. Preliminary results of a phase I/II study of HDR brachytherapy alone for early stage invasive breast carcinoma. *Int J Radiat Oncol Biol Phys*, 53:889-897; 2002.
- 100) J. Morr, T. DiPetrillo, M Engler, J-S Tsai, **D. E. Wazer**. The feasibility and utility of daily BAT ultrasound localization for the intensity-modulated treatment of localized prostate carcinoma. *Int J Radiat Oncol Biol Phys*, 53:1124-1129; 2002.
- 101) A. Neuschatz, T. DiPetrillo, **D. E. Wazer**. The value of breast lumpectomy margin assessment as a predictor of residual tumor burden in ductal carcinoma in situ of the breast. *Cancer* 94:1917-1924; 2002.
- 102) G. P. Dimri, J-L Martinez, JLL Jacobs, P Keblusek, K Itahana, M. van Lohuizen, J. Campisi, **D. E. Wazer**, V. Band. The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. *Cancer Res* 62:4736-4745;2002.
- 103) A. C. Neuschatz, T.A. DiPetrillo, H. Safaii, D. Lowther, M. Landa, **D. E. Wazer**. Margin width as a determinant of local control with and without radiation therapy for ductal carcinoma in situ (DCIS) of the breast. *Radiat Oncol Invest*, 96(suppl):97-104; 2001.
- 104) S. Dhar, R. Bhargava, M. Yunes, B. Li, J. Goyal, S. Naber, **D. E. Wazer**, V. Band. Analysis of normal epithelial specific-1 (NES1)/Kallikrein 10 mRNA expression by *in situ* hybridization, a novel marker for breast cancer. *Clin Cancer Res* 7:3393-3398;2001.
- 105) A. Kumar, Y. Zhao, G. Meng, M. Zeng, S. Srinivisan, L. Delmolino, Q. Gao, G. Dimri, G. Weber, **D. E. Wazer**, H. Band, V. Band. Human papilloma virus oncoprotein E6 inactivates the transcriptional coactivator human ADA3. *Molec Cell Biol*, 22:5801-5812; 2002.
- 106) G. Meng, Y. Zhao, M. Zeng, G. Dimri, Q. Gao, **D.E. Wazer**, H. Band, V. Band. Human ADA3 binds to ER and functions as co-activator for ER-mediated transactivation. *J Biol Chem* 279:54230-40; 2004.
- 107) M. Zeng, A. Kumar, Y. Zhao, G. Meng, Q. Gao, G. Dimri, **D.E. Wazer**, H. Band. V. Band. Human papilloma virus 16 E6 oncoprotein inhibits retinoic X receptor-mediated transactivation by targeting human ADA3 coactivator. *J Biol Chem* 277(47):45611-45618; 2002.

- 108) D.W. Arthur, R.R. Kuske, F. Vicini, **D.E. Wazer**, S. Nag, for the American Brachytherapy Society. Accelerated Partial Breast Irradiation: An updated report from the American Brachytherapy Society. *Brachytherapy* 1:184-190; 2002.
- 109) M.J. Rivard, L.J. Stapleford, K.E. Evans and **D.E. Wazer**. A radiobiological model for the relative biological effectiveness of high dose rate Cf-252 brachytherapy. *Radiat Res* 164:319-323; 2005.
- 110) M.A. Chung, T. DiPetrillo, S. Hernandez, G. Masko, **D. Wazer**, B. Cady. Treatment of the axilla by tangential breast radiotherapy in women with invasive breast cancer. *Am J Surg* 184(5):401-402; 2002.
- 111) J-S. Tsai, M.J. Rivard, M.J. Engler, J.E. Mignano. W. A. Shucart, **D. E. Wazer**. Determination of the 4 mm gamma knife helmet relative output factor using a variety of detectors. *Med Phys* 30:986-92; 2003.
- 112) A.C. Neuschatz, T. DiPetrillo, H. Safaii, L. L. Price, R. K. Schmidt-Ullrich, **D. E. Wazer**. Long-term follow-up of a prospective policy of margin-directed radiation dose escalation in breast-conserving therapy. *Cancer* 97:30-39; 2003.
- 113) L. Singh, Q. Gao, A. Kumar, T. Gotoh, **D. E. Wazer**, H. Band, L.A. Feig, V. Band. The high-risk human papillomavirus type 16 E6 counters the GAP function of E6TP1 toward small Rap G proteins. *J Virol* 77:1614-1620; 2003.
- 114) P. Zhou, N. Fernandes, I.L. Dodge, A.L. Reddi, N. Rao, H. Safran, T. A. DiPetrillo, **D.E. Wazer**, V. Band, H. Band. ErbB2 degradation mediated by the co-chaperone protein CHIP. *J Biol Chem* 278:13829-37; 2003.
- 115) J.K. Marshall, K.A. Griffith, B.G. Haffty, L.J. Solin, F.A. Vicini, B. McCormick, **D. E. Wazer**, A. Recht, L.J. Pierce. Conservative management of Paget disease of the breast with radiotherapy. *Cancer* 97:2142-2149; 2003.
- 116) N. Shah, T. Tenenholz, D. Arthur, T. DiPetrillo, B. Bornstein, G. Cardarelli, Z. Zheng, M. Rivard, S. Kaufman, **D. E. Wazer**. Mammosite and interstitial brachytherapy for accelerated partial breast irradiation: factors affecting toxicity and cosmesis. *Cancer*, 101:727-734; 2004.
- 117) H. D. Zinkin, M. Rivard, J. Mignano, **D. E. Wazer**. Analysis of dose conformity and normal-tissue sparing using two different IMRT prescription methodologies for irregularly shaped CNS lesions irradiated with the Beak and 1 cm MIMiC collimators. *Int J Radiat Oncol Biol Phys* 59:285-292; 2004.
- 118) M.J. Rivard, B.L. Kirk, L.J. Stapleford, **D.E. Wazer**. A comparison of the expected costs of high dose rate brachytherapy using 252Cf versus 192Ir. *Appl Radiat Isot* 61:1211-1216; 2004.
- 119) D.W. Arthur, F. A. Vicini, R. R. Kuske, **D. E. Wazer**, S. Nag. Accelerated partial breast

irradiation: an updated report from the American Brachytherapy Society. *Brachytherapy* 2:124-130; 2003.

- 120) X. Tian, D. Rai, J. Li, C. Zou, Y. Bai, **D. E. Wazer**, V. Band, Q. Gao. BRCA2 suppresses cell proliferation via stabilizing MAGE-D1. *Cancer Res* 65:4747-4753; 2005
- 121) **D. E. Wazer**, S. Kaufman, L. Cuttino, T. DiPetrillo, D. W. Arthur. Accelerated Partial Breast Irradiation: An analysis of variables associated with late toxicity and long-term cosmetic outcome after HDR interstitial brachytherapy. *Int J Radiat Oncol Biol Phys*, 64:489-495; 2006.
- 122) S. Kaufman, A Neuchatz, T. DiPetrillo, **D. E. Wazer**. MammoSite excision volume as a predictor of residual disease. *Cancer* 104:906-912; 2005.
- 123) J. Li, C. Zou, Y. Bai, **D. E. Wazer**, V. Band, Q. Gao. DSS1 is required for the stability of BRCA2. *Oncogene*, 25:1186-1194; 2006.
- 124) C. Zou, J. Li, Y. Bai, W. Gunning, **D. E. Wazer**, V. Band, Q. Gao. Centrobin: A novel daughter centriole-associated protein that is required for centriole duplication. *J Cell Biol* 171:437-445; 2005.
- 125) G. Cardarelli, M. Rivard, J. Tsai, N. O'Connell, J. Hiatt, T. DiPetrillo, N. Shah, D. Shearer, **D. E. Wazer**. Multiple dwell positions for the Mammosite HDR Ir-192 brachytherapy applicator. *Brachytherapy*, in press.
- 126) Kim J, Zhang X, Rieger-Christ KM, Summerhayes IC, **D. E. Wazer**, Paulson KE, Yee AS. Suppression of WNT signaling by the green tea compound EGCG in invasive breast cancer cells: Requirement of the transcriptional repressor HBP1. *J Biol Chem* 2006 [Epub ahead of print]

## TEXTBOOKS AND MONOGRAPHS

- 1) **D.E. Wazer**, guest editor of "Surgical Oncology Clinics of North America", "Practical Radiation Oncology for the Surgical Oncologist", W.B. Saunders Co., Philadelphia, PA; July, 2000.
- 2) **D. E. Wazer**, co-editor (with R. Schmidt-Ullrich, T. Bortfeld, W. De Neve), "Image-guided IMRT". Springer-Verlag., Heidelberg. Released in December 2005.
- 3) **D. E. Wazer**, lead and managing editor. Co-editors, D. Arthur and F. Vicini. "Accelerated Partial Breast Irradiation". Springer-Verlag, in production.
- 4) **D. E. Wazer**, associate editor (with E. Halperin, C. Perez, and L. Brady) "Principles and Practice of Radiation Oncology, 5<sup>th</sup> Edition". Lippincott, Williams, and Wilkins, In production.

## REVIEW ARTICLES AND BOOK CHAPTERS

- 1) **D. Wazer**, J. Rotrosen, M. Stanley; The Benzamides: Evidence for action at dopamine receptors - shortcomings of current models. in, "The Benzamides", Advances in Biochem. Psychopharm. Series. Vol. 35, Raven Press, New York, 1982.
- 2) N. Robert, **D. E. Wazer**, T. Smith, M. Homer, H. Safaii, and D. Marchant; In Situ Breast Cancer: A Multidisciplinary Approach. Hospital Practice 24(4);169-185, 1989.
- 3) M. Sinesi and **D. E. Wazer**; Radiation Therapy for Tumors of the Ear and Periauricular Region. In "Cutaneous Tumors of the Head and Neck", eds. G. Rogers, Plenum Press, 1990.
- 4) M. Chun, **D.E. Wazer**, H. Madoc-Jones; Radiation Therapy and Anesthesia. in "Yearbook of Anesthesia", Yearbook medical publishers, 1990.
- 5) T. Smith, **D. E. Wazer**, N. J. Robert, M. Homer, H. Safaii. Local/regional therapy of primary breast cancer; A contemporary multimodal approach. Seminars in Oncology, 19(3):230-238, 1992.
- 6) **D. E. Wazer**, R. Zamenhof, H. Madoc-Jones. Boron Neutron Capture Therapy. In "Radiation Oncology: Technology and Biology", eds. P. Mauch and J. Loeffler, W. B. Saunders, 1994.
- 7) **D. E. Wazer**. Invasive Breast Cancer - Treatment Alternatives. In "Contemporary Management of Breast Cancer", Obstetrics and Gynecology Clinics of North America, W. B. Saunders, 1994.
- 8) **D. E. Wazer**, R. Zamenhof, H. Madoc-Jones, O. K. Harling; Boron Neutron Capture Therapy. In "Cancer of the Nervous System", P. Mcl. Black and J. Loeffler, eds., Blackwell Scientific Publications, Cambridge, Mass. 1997.
- 9) **D. E. Wazer**. Radiation Therapy in the management of early invasive breast cancer. In,"Breast Disease". D. Marchant, ed., W.B. Saunders, 1997.
- 10) **D.E. Wazer**. Approaches to clinical applications of intensity-modulated radiation therapy for malignant tumors of the CNS. In, "The Theory and Practice of Intensity Modulated Radiation Therapy". E. S. Sternick, ed., Advanced Medical Publishing, Madison, WI, 1997.
- 11) **D.E. Wazer**. Regionally metastatic melanoma: The management of "high risk" lymph node basins. In, "The Melanoma Newsletter", M. Atkins, J. Kirkwood, eds. Marcel-Decker, New York, 1996.
- 12) **D.E. Wazer**. Contemporary issues in the use of radiation therapy for early invasive breast cancer. Seminars in Surgical Oncology, "*Practical Radiation Oncology for the Surgical Oncologist*", ed. D. E. Wazer. Pp. 585-601, July, 2000.
- 13) **D.E. Wazer**. The role of radiation therapy in the management of melanoma. *UpToDate in Oncology* (CD-ROM), Volume 8, No. 1, 2000.

- 14) M. Engler, J-S Tsai, T. DiPetrillo, **D.E. Wazer**. Commissioning and quality assurance of sequential tomotherapy systems. In, "The Target Volume in Radiotherapy: 3D Treatment Planning for the Clinician", L. Verhey, M. Roach, eds. Symposium Proceedings, UCSF, 2000.
- 15) **D.E. Wazer**. DCIS patient selection: Who should be treated with radiotherapy? Syllabus for the American College of Surgeons Postgraduate Course in Breast Cancer, Proceedings of the 2000 Clinical Congress, Volume 21, pp. 9-12, October, 2000.
- 16) M.J. Engler, J-S. Tsai, T. DiPetrillo, **D.E. Wazer**. Optimization Strategies for Inverse Planning. Proceedings of the 5<sup>th</sup> International Symposium on 3D Conformal Radiation Therapy and Brachytherapy, Memorial Sloan-Kettering Cancer center, New York, NY, June 1-3, 2000, pp 329-332.
- 17) M.A. Chung, **D.E. Wazer**, B. Cady. Contemporary management of breast cancer. Pp 173-188, In, "Breast Diseases: Diagnosis and Contemporary Management", D. J. Marchant, ed. Obstetrics and Gynecology Clinics of North America, Volume 29, number 1, March, 2002. W. B. Saunders Company, Philadelphia, PA
- 18) **D.E. Wazer**. Melanoma. A web-based reference resource through [www.cancerdata.com](http://www.cancerdata.com)
- 19) M.J. Engler, J. Tsai, T. DiPetrillo, **D.E. Wazer**. Patient Specific IMRT Quality Assurance Issues. In, *3-D Conformal and Intensity Modulated Radiation Therapy: Physics and Clinical Applications*. JA Purdy, WH Grant, JR Palta, EB Butler, CA Perez, eds. Advanced Medical Publishing, Inc, Madison, WI, 2001. Pgs 333-344.
- 20) **D.E. Wazer**, T. DiPetrillo, J. Tsai, M. Engler, C. Godin, P. Pagnini. New England Medical Center Prostate IMRT Experience. In, *3-D Conformal and Intensity Modulated Radiation Therapy: Physics and Clinical Applications*. JA Purdy, WH Grant, JR Palta, EB Butler, CA Perez, eds. Advanced Medical Publishing, Inc, Madison, WI, 2001. Pgs: 457-462.
- 21) T. A. DiPetrillo, **D.E. Wazer**, M. Engler, J. Tsai, T. Boyle. Head and Neck IMRT: New England Medical Center Experience. In, *3-D Conformal and Intensity Modulated Radiation Therapy: Physics and Clinical Applications*. JA Purdy, WH Grant, JR Palta, EB Butler, CA Perez, eds. Advanced Medical Publishing, Inc, Madison, WI, 2001. Pgs: 523-528.
- 22) **D. E. Wazer** and D. W. Arthur. Stage Tis Breast Cancer. In, *Principles and Practice of Radiation Oncology*. C Perez, L Brady, R Schmidt-Ullrich, E. Halperin, eds. Lippincott, Williams and Wilkins, Philadelphia, PA, 2003.
- 23) T. A. Buchholz and **D. E. Wazer**. Molecular biology and genetics of breast cancer development: A clinical perspective. *Seminars in Radiation Oncology* 12(4):285-295; 2002.
- 24) N. Shah and **D. E. Wazer**. The Mammosite balloon catheter for accelerated partial breast irradiation. *Seminars in Radiation Oncology*, 15:100-107;2005.

- 25) S. Benedict, J. Purviance, D. Song, **D. E. Wazer**. Small Field High-Precision IMRT. In, *Intensity Modulated Radiation Therapy*. R. Schmidt-Ullrich, T. Bortfeld, W. De Neve, D. E. Wazer, eds. Springer-Verlag.
- 26) **D.E. Wazer** and D. W. Arthur. Breast: Stage Tis. In *Principles and Practice of Radiation Oncology, 5<sup>th</sup> edition*. C. Perez, L. Brady, E. Halperin, D. E. Wazer, C. Freeman, L. Prosnitz, eds. Lippincott, Williams & Wilkins, in press.
- 27) Y. Zhang, I. Bhat, M. Zeng, J. Goyal, **D. E. Wazer**, H. Band, V. Band. Human Kallikrein 10: a predictive marker for breast cancer. *Biol Chem*, in press.
- 28) M. J. Rivard, A. Taghian, **D. E. Wazer**. New and novel treatment delivery techniques for accelerated partial breast irradiation. In, *Accelerated Partial Breast Irradiation*. D. E. Wazer, D. Arthur, F. Vicini, eds. Springer-Verlag, in press.
- 29) D. Arthur, F. Vicini, **D. E. Wazer**. Who is a candidate for accelerated partial breast irradiation? In, *Accelerated Partial Breast Irradiation*. D. E. Wazer, D. Arthur, F. Vicini, eds. Springer-Verlag, in press.
- 30) D. E. Wazer. Normal tissue toxicity after accelerated partial breast irradiation. In, *Accelerated Partial Breast Irradiation*. D. E. Wazer, D. Arthur, F. Vicini, eds. Springer-Verlag, in press.

## EDITORIALS

- 1) **D. Wazer** and B. Willett; Clinical considerations in palliative treatment of metastatic prostate carcinoma. *Int. J. Radiat. Biol. Oncol. Phys.* **13**:145-146, 1987.
- 2) S. Krosnick and **D. Wazer**; A linear quadratic analysis of differing fractionation schemes for prophylactic cranial irradiation. *J. Clin. Oncol.* **9**(8):1599-1600, 1990.
- 3) J. Erban, T. Smith, **D. Wazer**, A review of "Breast Diseases" by J. Harris, et al. *New England Journal of Medicine*, **326**(10):715, 1992.
- 4) **D. E. Wazer**, R. Schmidt-Ullrich. Impact of time on cosmetic outcome following breast conserving therapy. Editorial reply. *J Clin Oncol* **10**:1201. 1992.
- 5) R. Schmidt-Ullrich, **D. E. Wazer**, T. DiPetrillo; Optimal management of the tumor-bearing quadrant in the setting of breast-conserving therapy. Editorial Reply. *Int. J. Radiat. Oncol. Biol. Phys.* **27**:757-758, 1993.
- 6) **D. E. Wazer**. Eat less, exercise more - don't have cancer. *The Middlesex News* (op/ed page), January 3, 1997.
- 7) J. M. Kirkwood, **D. E. Wazer**, M. Rosenstein. Interferon adjuvant therapy of melanoma. *Cancer* **79**:1843-1845, 1997.

- 8.) K. Miller, D. Schenkein, G. Jabro, Y. Koc, T. Boyle, J. Ravalese, **D. E. Wazer**. Response to Gratwohl et al: Role of splenic irradiation in patients with chronic myelogenous leukemia undergoing allogeneic bone marrow transplant. *Biology of Blood and Marrow transplantation* 6:213, 2000.
- 9.) **D. E. Wazer**. Commentary on, "Mammographically detected ductal carcinoma in situ of the breast treated with breast conserving surgery and definitive breast irradiation". *Breast Diseases: A Year Book Quarterly*, in press.
- 10.) F. A. Vicini, D. W. Arthur, **D. E. Wazer**. Inconsistency, perspective, double talk, and false virtue. *Brachytherapy* 1:181-183; 2002.
- 11.) **D. E. Wazer**. A remembrance of Rupert K. A. Schmidt-Ullrich. *Int J Radiat Oncol Biol Phys*, 62:1-2; 2005.
- 12.) **D. E. Wazer**. The American Journal of Clinical Oncology and the American College of Radiation Oncology: A partnership for the future. *Am J Clin Oncol* 29:1-2; 2006
- 13.) **D.E. Wazer**. Early results of a registry trial with MammoSite for partial breast irradiation. *Women's Oncology Review*, in press.